Scholarlink

Background <p>Endometrial carcinoma (EC) is one of the most common gynecological malignancies, showing rising incidence worldwide. Recent evidence suggests that tumor behavior is influenced by hormonal status, angiogenesis, and tumor budding. This study aimed to evaluate the expression and clinicopathological significance of estrogen receptor (ER), progesterone receptor (PR), microvessel density (MVD), and tumor budding in EC.</p> Methods <p>This cross-sectional study included 44 histologically confirmed cases of EC. ER and PR expression were assessed using immunohistochemistry. Tumor budding was quantified as per standardized protocols, and MVD was evaluated using CD34 staining. Associations with clinicopathological parameters were analyzed using Chi-square test.</p> Results <p>ER and PR were positive in 81.8% and 93.2% of cases respectively. High ER/PR expression correlated with endometrioid subtype (<i>p</i> = 0.035 and 0.024) and &gt; 50% myometrial invasion (<i>p</i> = 0.036 and 0.018). Tumor budding was present in 61.4% of cases and significantly associated with endometrioid histology, early FIGO stage, and wild-type p53 pattern (<i>p</i> = 0.034, 0.01, and 0.047, respectively). MVD was significantly elevated in premenopausal patients and early-stage tumors (<i>p</i> &lt; 0.01 and 0.03).</p> Conclusion <p>Hormone receptor positivity, angiogenesis, and tumor budding are interrelated features reflecting tumor biology and prognosis in EC. Integrating these parameters can aid in risk stratification and personalized management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinicopathological Correlation of Hormone Receptors, Angiogenesis, and Tumor Budding in Endometrial Carcinoma: A Tertiary Care Center Study

  • 期刊论文

  • 发表日期：

    2025年11月3日

查看全文
  • Senjuti Dasgupta,
  • Arpita Das,
  • Ujjwal Bandyopadhyay

摘要

Background

Endometrial carcinoma (EC) is one of the most common gynecological malignancies, showing rising incidence worldwide. Recent evidence suggests that tumor behavior is influenced by hormonal status, angiogenesis, and tumor budding. This study aimed to evaluate the expression and clinicopathological significance of estrogen receptor (ER), progesterone receptor (PR), microvessel density (MVD), and tumor budding in EC.

Methods

This cross-sectional study included 44 histologically confirmed cases of EC. ER and PR expression were assessed using immunohistochemistry. Tumor budding was quantified as per standardized protocols, and MVD was evaluated using CD34 staining. Associations with clinicopathological parameters were analyzed using Chi-square test.

Results

ER and PR were positive in 81.8% and 93.2% of cases respectively. High ER/PR expression correlated with endometrioid subtype (p = 0.035 and 0.024) and > 50% myometrial invasion (p = 0.036 and 0.018). Tumor budding was present in 61.4% of cases and significantly associated with endometrioid histology, early FIGO stage, and wild-type p53 pattern (p = 0.034, 0.01, and 0.047, respectively). MVD was significantly elevated in premenopausal patients and early-stage tumors (p < 0.01 and 0.03).

Conclusion

Hormone receptor positivity, angiogenesis, and tumor budding are interrelated features reflecting tumor biology and prognosis in EC. Integrating these parameters can aid in risk stratification and personalized management.